Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Baxter International Inc.NYSE: BAX
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $126M rose 3.3% year over year, behind the +304.6% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -32.5% a year.
Context
- Net income amounted to 8.5% of revenue in FY2025, up 5.4 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of $1.09B (+213.9%) for the fiscal year ending Dec 2026, a step up from the +193.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $126M+940.0% QoQ
- Last fiscal yearDec 2025
- -$957M+193.6% YoY
- LTMJun 2026
- -$975M+304.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.3% | +628.4% | +625.1 pp |
| 1 year | +193.6% | +213.9% | +20.3 pp |
| 3-year CAGR | -32.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (957M) USD
- Year-over-year change
- -193.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (957M) | -193.6% |
| FY2024 | 2024-12-31 | (326M) | -280.1% |
| FY2023 | 2023-12-31 | 181M | +105.8% |
| FY2022 | 2022-12-31 | (3.11B) | -401.4% |
| FY2021 | 2021-12-31 | 1.03B | — |
Net Income vs competitors
How BAX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +304.6% is the highest of 5, against a peer median of +95.4%.
- Net income amounts to 8.5% of revenue for BAX, versus a peer median of 5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.26B USD | +16.2% | +11.3% | 9.0% | |
| LTM Jun 2026 | €1.06B EUR | +42.9% | +1.7% | 5.5% | |
| LTM Jun 2026 | $975M USD | +304.6% | -32.5% | 8.5% | |
| LTM Jun 2026 | $30.09M USD | +181.4% | — | 1.4% | |
| LTM Mar 2026 | $7.91M USD | +148.0% | +616.7% | 5.6% | |
| Peer median (excluding BAX) | — | +95.4% | +11.3% | 5.5% | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.03B | (3.11B) | 181M | (326M) | (957M) |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| Deferred Income Tax | (161M) | (260M) | (256M) | (262M) | 77M |
| Stock-Based Compensation | 146M | 140M | 115M | 114M | 117M |
| Change in Working Capital | (57M) | (606M) | 161M | (236M) | (108M) |
| Accounts Receivables | (170M) | (48M) | (38M) | (35M) | (132M) |
| Inventory | (27M) | (198M) | (128M) | (201M) | (119M) |
| Accounts Payables | 105M | (67M) | 92M | 112M | 3M |
| Other Working Capital | 35M | (293M) | 235M | (112M) | 140M |
| Other Non-Cash Items | 394M | 3.98B | 541M | 732M | 735M |
| Operating Cash Flow | 2.22B | 1.21B | 1.73B | 1.02B | 845M |
| Capital Expenditures | (691M) | (635M) | (436M) | (460M) | (522M) |
| Acquisitions (Net) | (10.5B) | (263M) | (6M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 34M | 0 |
| Other Investing Activities | (7M) | (33M) | 3.66B | (200M) | 3.35B |
| Investing Cash Flow | (11.2B) | (931M) | 3.21B | (626M) | 2.84B |
| Debt Repayment | 9.33B | (899M) | (2.94B) | (531M) | (3.79B) |
| Common Stock Issued | 187M | 127M | 95M | 71M | 30M |
| Common Stock Repurchased | (600M) | (32M) | 0 | 0 | 0 |
| Dividends Paid | (530M) | (573M) | (586M) | (590M) | (348M) |
| Other Financing Activities | (138M) | (61M) | (63M) | (31M) | (107M) |
| Financing Cash Flow | 8.25B | (1.44B) | (3.49B) | (1.08B) | (4.22B) |
| Effect of Forex Changes | (47M) | (76M) | 26M | (96M) | 84M |
| Net Change in Cash | (780M) | (1.23B) | 1.48B | (784M) | (446M) |
| Free Cash Flow | 1.53B | 576M | 1.29B | 559M | 323M |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.